BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26153495)

  • 1. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
    Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
    Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
    Atreya CE; Greene C; McWhirter RM; Ikram NS; Allen IE; Van Loon K; Venook AP; Yeh BM; Behr SC
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1536-1543. PubMed ID: 27956538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.
    Morris VK; Lucas FAS; Overman MJ; Eng C; Morelli MP; Jiang ZQ; Luthra R; Meric-Bernstam F; Maru D; Scheet P; Kopetz S; Vilar E
    Ann Oncol; 2014 Oct; 25(10):2008-2014. PubMed ID: 25009008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of
    de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
    Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in KRAS/NRAS/BRAF-Mutation Status by Age, Sex, and Race/Ethnicity Among a Large Cohort of Patients with Metastatic Colorectal Cancer (mCRC).
    Booker BD; Markt SC; Schumacher FR; Rose J; Cooper G; Selfridge JE; Koroukian SM
    J Gastrointest Cancer; 2024 Mar; 55(1):237-246. PubMed ID: 37355486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with BRAF
    Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C
    ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
    Kopetz S; Guthrie KA; Morris VK; Lenz HJ; Magliocco AM; Maru D; Yan Y; Lanman R; Manyam G; Hong DS; Sorokin A; Atreya CE; Diaz LA; Allegra C; Raghav KP; Wang SE; Lieu CH; McDonough SL; Philip PA; Hochster HS
    J Clin Oncol; 2021 Feb; 39(4):285-294. PubMed ID: 33356422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
    Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
    Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
    Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU
    J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
    Kosumi K; Hamada T; Zhang S; Liu L; da Silva A; Koh H; Twombly TS; Mima K; Morikawa T; Song M; Nowak JA; Nishihara R; Saltz LB; Niedzwiecki D; Ou FS; Zemla T; Mayer RJ; Baba H; Ng K; Giannakis M; Zhang X; Wu K; Giovannucci EL; Chan AT; Fuchs CS; Meyerhardt JA; Ogino S
    Eur J Cancer; 2019 Apr; 111():82-93. PubMed ID: 30826660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
    Schafroth C; Galván JA; Centeno I; Koelzer VH; Dawson HE; Sokol L; Rieger G; Berger MD; Hädrich M; Rosenberg R; Nitsche U; Schnüriger B; Langer R; Inderbitzin D; Lugli A; Zlobec I
    Oncotarget; 2015 Dec; 6(39):41453-63. PubMed ID: 26496026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on
    Schietroma F; Anghelone A; Valente G; Beccia V; Caira G; Spring A; Trovato G; Di Bello A; Ceccarelli A; Chiofalo L; Perazzo S; Bensi M; Minucci A; Urbani A; Larocca LM; Basso M; Pozzo C; Salvatore L; Calegari MA; Tortora G
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473349
    [No Abstract]   [Full Text] [Related]  

  • 15. Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts.
    Osterlund E; Ristimäki A; Mäkinen MJ; Kytölä S; Kononen J; Pfeiffer P; Soveri LM; Keinänen M; Sorbye H; Nunes L; Salminen T; Nieminen L; Uutela A; Halonen P; Ålgars A; Sundström J; Kallio R; Ristamäki R; Lamminmäki A; Stedt H; Heervä E; Kuopio T; Sjöblom T; Isoniemi H; Glimelius B; Osterlund P
    Int J Cancer; 2024 Feb; 154(3):488-503. PubMed ID: 37724848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis.
    Rebersek M; Boc M; Cerkovnik P; Benedik J; Hlebanja Z; Volk N; Novakovic S; Ocvirk J
    Radiol Oncol; 2011 Dec; 45(4):285-91. PubMed ID: 22933967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.
    Zeng C; Wang M; Xie S; Wang N; Wang Z; Yi D; Kong F; Chen L
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16111-16121. PubMed ID: 37639010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.
    Johnson B; Kopetz S
    Target Oncol; 2020 Oct; 15(5):567-577. PubMed ID: 32889679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
    Ambrosini-Spaltro A; Rengucci C; Capelli L; Chiadini E; Calistri D; Bennati C; Cravero P; Limarzi F; Nosseir S; Panzacchi R; Valli M; Ulivi P; Rossi G
    Curr Oncol; 2023 Nov; 30(11):10019-10032. PubMed ID: 37999148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future.
    Djanani A; Eller S; Öfner D; Troppmair J; Maglione M
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.